Floatz logo

Mesna

Lymphoma, Large-Cell, Diffuse

The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lymphoma, Large-Cell, Diffuse cohort.

Asset / SponsorPhaseRating
Humax-Cd20
SCRI Development Innovations, LLC
Phase 3BB
BLEOMYCIN
Nanfang Hospital, Southern Medical University
Phase 3BB
Granulocyte-Macrophage Colony Stimulating Factor
National Cancer Institute (NCI)
Phase 2B
SEPANTRONIUM
Astellas Pharma Inc
Phase 2CCC
ptk787
David Rizzieri, MD
Phase 2CCC

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
69 / 100
View asset →
NK/T-cell LymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →